Jingjing Zhou

A Tumor-Microenvironment-Responsive Chemically MaskedIL-2 Prodrug Potentiates PD-1 Checkpoint Blockade andElicits Robust Antitumor Efficacy

Abstract Interleukin-2 (IL-2) is a potent mediator of T-cell activation with significant potential for cancer immunotherapy, yet its clinical utility is severely constrained by its narrow therapeutic window. Here we report a chemically masked IL-2 prodrug (Cm-proIL2) that enables...